Successful percutaneous radiologic management of renal cell carcinoma tumor seeding caused by percutaneous biopsy performed before ablation.

J Vasc Interv Radiol

Division of Abdominal Imaging and Intervention, Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. nsainani@ partners.org

Published: September 2013

A case is reported of the successful image-based detection, diagnosis, and percutaneous ablation of tumor seeding in a 61-year-old man that was caused by percutaneous biopsy of a renal cell carcinoma performed before cryoablation and was not detected until 4 years after the biopsy procedure. Although tumor seeding is a rare complication after percutaneous biopsy or ablation, this case emphasizes the importance of imaging surveillance of the needle tract used during both biopsy and ablation procedures, provides guidance on measures that can be used to minimize the occurrence of tumor seeding, and demonstrates that entirely radiologic management can be successful.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jvir.2013.04.034DOI Listing

Publication Analysis

Top Keywords

tumor seeding
16
percutaneous biopsy
12
radiologic management
8
renal cell
8
cell carcinoma
8
caused percutaneous
8
ablation case
8
biopsy ablation
8
biopsy
5
successful percutaneous
4

Similar Publications

Glioblastoma (GBM) is the most common malignant primary brain tumor, with a mean survival of less than 2 years. Unique brain structures and the microenvironment, including blood-brain barriers, put great challenges on clinical drug development. Sophoricoside (Sop), an isoflavone glycoside isolated from seeds of Sophora japonica L.

View Article and Find Full Text PDF

Purpose: This study evaluates the feasibility of utilizing robotic-assisted bronchoscopy with cone beam computed tomography (RB-CBCT) platform to perform low-dose-rate brachytherapy implants (LDR-BT) in a mechanically ventilated human cadaveric model. Post-implant dosimetry was compared to standard stereotactic body radiation therapy plans (SBRT).

Materials And Methods: The RB-CBCT platform was used to place inert LDR-BT seeds into mechanically ventilated human cadavers with percutaneously injected pseudotumors.

View Article and Find Full Text PDF

Seeding Janus Zn-Fe Diatomic Pairs on a Hollow Nanobox for Potent Catalytic Therapy.

Nano Lett

January 2025

Key Laboratory of Superlight Materials and Surface Technology, Ministry of Education, College of Material Sciences and Chemical Engineering, Harbin Engineering University, Harbin 150001, P. R. China.

Dual atomic nanozymes (DAzymes) are promising for applications in the field of tumor catalytic therapy. Here, integrating with ultrasmall FeC nanoclusters, asymmetric coordination featuring Janus Zn-Fe dual-atom sites with an ON-Fe-Zn-N moiety embedded in a carbon vacancy-engineered hollow nanobox (Janus ZnFe DAs-FeC) was elaborately developed. Theoretical calculation revealed that the synergistic effects of Zn centers acting as both adsorption and active sites, oxygen-heteroatom doping, carbon vacancy, and FeC nanoclusters jointly downshifted the d-band center of Fe 3d orbitals, optimizing the desorption behaviors of intermediates *OH, thereby significantly promoting catalytic activity.

View Article and Find Full Text PDF

Brain metastases (BrMets), common for advanced-stage breast cancer patients, are associated with poor median survival and accompanied by severe neurologic decline. Halting the progression of breast cancer brain metastases (BCBMs) may require modulation of the tumor microenvironment (TME), yet little is known about the impact of the primary breast TME on brain tropism, or how, once there, metastatic breast cancer cells coexist with brain-resident cells (e.g.

View Article and Find Full Text PDF

Objective: The objective of this study was to evaluate the efficacy and safety of TACE combined with 125I seeds (TACE-125I) in the treatment of recurrent HCC at complex sites after hepatectomy.

Methods: This study retrospectively analyzed the clinical data of recurrent HCC patients located at complex sites (such as large blood vessels, diaphragm dome, etc.) after hepatectomy from January 2012 to December 2023, all of whom received TACE-125I or TACE therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!